Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021.

ABSTRACT: The 50% plaque reduction neutralization assay (PRNT₅₀) has been previously used to assess the neutralization capacity of donor plasma against wild-type and variant of concern (VOC) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerging data suggest that plasma with an anti-SARS-CoV-2 level of ≥2 × 10⁴ binding antibody units/mL (BAU/mL) protects against SARS-CoV-2 Omicron BA.1 infection. Specimens were collected using a cross-sectional random sampling approach. For PRNT₅₀ studies, 63 previously analyzed specimens by PRNT₅₀ versus SARS-CoV-2 wild-type, Alpha, Beta, Gamma, and Delta were analyzed by PRNT₅₀ versus Omicron BA.1. The 63 specimens plus 4,390 specimens (randomly sampled regardless of serological evidence of inf

SUBMITTER: Lin YJ 

PROVIDER: S-EPMC10434250 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature